TrialJournal of hematology & oncology2020

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.